Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 12/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 12/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432974 | 0.90 | SLC2A1 (0.60) | KDM4EGAASLC2A1HTTGABRB2 | |
| SCHEMBL1430932 | 0.86 | SLC2A3 (0.56) | KDM4EGAASLC2A1KCNK3KCNK9 | |
| SCHEMBL2275313 | 0.85 | SLC2A1 (0.58) | KDM4ESLC2A1HTTGABRB2 | |
| SCHEMBL1430392 | 0.84 | KDM4E (0.60) | KDM4EGAASLC2A1NPC1POLB | |
| SCHEMBL1430081 | 0.84 | KDM4E (0.57) | KDM4EGAASLC2A1NPC1POLB | |
| SCHEMBL1430341 | 0.82 | KDM4E (0.57) | KDM4EGAASLC2A1NPC1POLB | |
| SCHEMBL1430172 | 0.82 | KDM4E (0.58) | KDM4EGAASLC2A1NPC1POLB | |
| SCHEMBL1429960 | 0.82 | KDM4E (0.57) | KDM4EGAASLC2A1NPC1POLB | |
| SCHEMBL1430221 | 0.81 | KDM4E (0.67) | KDM4EGAASLC2A1NPC1POLB | |
| SCHEMBL2183516 | 0.81 | KDM4E (0.61) | KDM4EGAASLC2A1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | KDM4E 3088/4885GAA 218/4885SLC2A1 2033/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | KDM4E 3088/4885GAA 218/4885SLC2A1 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.